ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

icotrokinra

Also written as “JNJ-77242113”, “Icotrokinra” and “PN-235”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Colitis, Ulcerative · Crohn Disease, led by 2 companies.

Drug pageIcotrokinra: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 18, 202314 company-led studies, 7 open or runningLicense: Protagonist Therapeutics → Johnson & Johnson, 2017Next primary completion: Feb 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only137 open or runningphase 3since Oct 18, 2023Sep 21, 2021Feb 10, 2027phase 3 · NCT06807424
Protagonist Therapeuticsits history only10 open or runningphase 1since Oct 29, 2020Oct 29, 2020none ahead

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. 2017Johnson & Johnson licensed it from Protagonist TherapeuticsLicenseWorldwide rights from phase 2 on · agreed · Johnson & Johnson
  2. Oct 29, 2020First study: phase 1 study in Healthy VolunteersNew to Protagonist TherapeuticsProtagonist Therapeutics · NCT04621630 · 107 enrolled · Australia
  3. Sep 21, 2021Johnson & Johnson’s first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT05062200 · 36 enrolled · Japan
  4. Jan 24, 2022Phase 2 study in Plaque PsoriasisJohnson & Johnson · NCT05223868 · 255 enrolled · United States, Canada, France and more
  5. Apr 27, 2022Phase 2 study in Plaque PsoriasisJohnson & Johnson · NCT05357755 · 90 enrolled · United States, Canada, France and more
  6. May 3, 2022Phase 2 study in Plaque PsoriasisJohnson & Johnson · NCT05364554 · 227 enrolled · United States, Canada, France and more
  7. Jan 20, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05703841 · 30 enrolled · China
  8. Sep 15, 2023Phase 2 study in Colitis, UlcerativeJohnson & Johnson · NCT06049017 · 252 enrolled · United States, Argentina, Australia and more
  9. Oct 18, 20232 phase 3 studies in Plaque PsoriasisJohnson & Johnson · NCT06095115, NCT06095102
  10. Feb 29, 2024Phase 3 study in PsoriasisJohnson & Johnson · NCT06295692 · 19 enrolled · Japan
  11. Feb 29, 2024Named icotrokinraINNProposed as its International Nonproprietary Name in WHO's List 130 · before, JNJ-77242113, PN-235
  12. Jan 29, 2025Phase 3 study in Arthritis, PsoriaticJohnson & Johnson · NCT06807424 · 813 enrolled · United States, Argentina, Australia and more
  13. Mar 13, 2025Phase 3 study in Arthritis, PsoriaticJohnson & Johnson · NCT06878404 · 552 enrolled · United States, Argentina, Australia and more
  14. Sep 22, 20252 phase 3 studiesJohnson & Johnson · NCT07196748, NCT07196722

Ahead

  1. Feb 10, 2027Primary completion: phase 3 study in Arthritis, PsoriaticJohnson & Johnson · NCT06807424
  2. Jan 14, 2028Primary completion: phase 3 study in Colitis, UlcerativeJohnson & Johnson · NCT07196748
  3. Sep 19, 2028Primary completion: phase 3 study in Crohn DiseaseJohnson & Johnson · NCT07196722

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07196748Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonJan 14, 2028896
NCT07196722Crohn Disease · United States, Argentina, Australia and more3RecruitingJohnson & JohnsonSep 19, 20281,092
NCT06878404Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonMay 25, 2026552
NCT06807424Arthritis, Psoriatic · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonFeb 10, 2027813
NCT06295692Psoriasis · Japan3Active, not recruitingJohnson & JohnsonJan 14, 202519
NCT06095115Plaque Psoriasis · United States, Argentina, Australia and more3Active, not recruitingJohnson & JohnsonJul 29, 2024684
NCT06095102Plaque Psoriasis · United States, Argentina, Canada and more3Active, not recruitingJohnson & JohnsonJun 19, 2024311
NCT06049017Colitis, Ulcerative · United States, Argentina, Australia and more2CompletedJohnson & JohnsonSep 26, 2024252
NCT05703841Healthy · China1CompletedJohnson & JohnsonApr 7, 202330
NCT05364554Plaque Psoriasis · United States, Canada, France and more2CompletedJohnson & JohnsonSep 29, 2023227
NCT05357755Plaque Psoriasis · United States, Canada, France and more2CompletedJohnson & JohnsonMar 23, 202390
NCT05223868Plaque Psoriasis · United States, Canada, France and more2CompletedJohnson & JohnsonDec 15, 2022255
NCT05062200Healthy · Japan1CompletedJohnson & JohnsonSep 28, 202236
NCT04621630Healthy Volunteers · Australia1CompletedProtagonist TherapeuticsSep 19, 2021107

How it is read

Names in the registry

  • “JNJ-77242113”, 9 entries
  • “Icotrokinra”, 4 entries
  • “PN-235”, 1 entry

Codes read as this program: PN235.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.